Clinical predictor of survival following docetaxel‑based chemotherapy

摘要: Prostate cancer (PCa) is the most common type of in males USA and incidence increasing. For castration-resistant PCa (CRPC), previous studies have identified docetaxel-based chemotherapy as first-line therapy. In present study, efficacy was investigated a population patients with CRPC. This study included 26 individuals (mean age, 73 years) CRPC who were between July 2007 October 2012 at Kaohsiung Medical University Hospital (Kaohsiung, Taiwan). The regimen consisted intravenous docetaxel (70 mg/m2) once every four weeks plus oral prednisolone (5 mg) twice daily for five days. Prostate-specific antigen (PSA) response (defined PSA decrease >50% over weeks), time to progression, PCa-specific survival overall (OS) evaluated. these patients, mean level prior treatment 335.58 ng/ml. During follow-up, average number cycles approximately seven 15 (58%) achieved response. found significantly correlate OS (P=0.014 P=0.028, respectively). value nadir 89.97 ng/ml months. adverse event leucopenia, which affected 88% patients. results indicated that length occurrence leucopenia may impact feasible effective However, events, particularly high be cause concern.